Recurrent Epithelial Ovarian Cancer: An Update on Treatment
Recurrent Epithelial Ovarian Cancer: An Update on Treatment
ABSTRACT: An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
An estimated 75% of women with ovarian cancer present with advanced-stage (III or IV) disease. For patients with low residual disease (all lesions < 1 cm in size following surgical debulking), the risk for recurrence after completion of primary therapy is 60% to 70%; however, for women with large-volume residual disease, the risk is estimated at 80% to 85%.
We conducted a systematic review using the MEDLINE database, PubMed, EMBASE, and the Cochrane Library. The search was restricted to English-language articles published from 1979 through July 2012. Priority was given to articles reporting original research, in particular randomized controlled trials, although review articles and commentaries also were consulted. Recent abstracts of research presented at symposia and scientific conferences were also considered.
The selection of therapy for women with recurrent disease is in large part determined by response to first-line therapy. Specifically, recurrent ovarian cancer has been dichotomized to either platinum-sensitive (progression-free interval [PFI] > 6 months) or platinum-resistant (PFI ≤ 6 months) disease, with PFI predicting the expected response rate (RR) and duration of response.[2-5] Irrespective of treatment selected, recurrent ovarian cancer remains incurable. The goals of therapy should focus on palliation of cancer-related symptoms, prolongation of life, and optimization of quality of life. This review will focus on the medical treatment, specifically chemotherapy options, available for women with recurrent ovarian cancer.
Role of Timing in the Treatment of Recurrent Ovarian Cancer
Recurrent ovarian cancer can be heralded by onset of new symptoms, radiologic evidence of recurrent disease, or a rising CA-125 level in an asymptomatic patient. CA-125 elevation may precede radiologic detection or onset of symptoms by several months.[6,7] Although formal definitions of ovarian cancer recurrence and progression have been described, based on both clinical and CA-125 criteria, many patients present with either an asymptomatic, radiologic recurrence or an asymptomatic rise in CA-125 level without a radiographic correlate.[7,8]
Given that recurrent disease is incurable, the goals of therapy outlined earlier should guide decisions about initiation of subsequent therapy. In patients with symptomatic recurrence, immediate institution of treatment may be justified and warranted to palliate cancer-related symptoms. For asymptomatic recurrences (rising CA-125 level, for example), timing of therapy is much more controversial. Those who advocate institution of immediate treatment argue that treating small-volume disease is more likely to succeed in achieving a complete response following early intervention.[10-12] Advocates for delaying treatment emphasize that the goal of therapy is palliation, so that medical intervention should be deferred until symptom onset, given the lack of data to show that early treatment improves survival.
The controversy surrounding the appropriate timing of institution of therapy was addressed in a prospective study of 1,442 women with ovarian cancer. The trial was conducted among patients in full clinical remission, with a normal CA-125 level following completion of primary surgical treatment and platinum-based systemic therapy. Both investigators and patients were blinded. Serum CA-125 levels were checked every 3 months. Women whose CA-125 rose to a level twice above the upper limit of normal and remained asymptomatic (n = 527) were randomized to either immediate treatment or treatment when clinical or symptomatic recurrence occurred. Women randomized to immediate therapy initiated chemotherapy a median of 5 months earlier than those who initiated therapy with the onset of symptoms. Survival and remission duration were comparable between the two arms at 57-month follow-up. However, quality of life was worse for the women undergoing immediate treatment. The investigators concluded that early institution of second-line therapy did not benefit patients, advocating for treatment to be delayed until symptoms develop or patients have signs of recurrent disease.
Platinum-Sensitive Recurrent Ovarian Cancer
Importance of the platinum-free interval
In general, platinum-sensitive recurrent ovarian cancer is treated with a platinum agent alone or in combination with another agent. When selecting single-agent vs combination therapy, it is important to consider the patient’s performance status, other comorbidites, and previous toxicities with other therapies. If combination therapy is elected, then the specific combination regimen chosen should also take these factors into account, to optimize outcome and minimize overlapping toxicities. The platinum-free interval—the time between the last cycle of platinum and evidence of disease progression—is now accepted as an important, significant predictor of response to second-line chemotherapy (see Table 1). Some experts have proposed that early use of nonplatinum agents can prolong the platinum-free interval and optimize subsequent retreatment with platinum.
A phase II trial randomly assigning patients with platinum-sensitive recurrences to either single-agent paclitaxel or combination therapy with cisplatin, doxorubicin, and cyclophosphamide documented similar overall response rates between the two regimens (45% vs 55%) but showed that the platinum-containing combination was associated with a significant increase in response duration (16 vs 9 months) and median survival (35 vs 26 months). This study is limited by its small sample size, phase II design, and the fact that close to 50% of the patients dropped out of the trial at “cross-over.”[15,16] However, the study results are used to advocate the use of platinum first in the management of women with platinum-sensitive recurrent ovarian cancer.[15,16] The choice of whether to use a single platinum agent or a platinum-containing combination should take into account the individual patient’s specific circumstances, beyond the disease-free interval for patients on platinum therapy. Combination regimens are associated with a longer response rate and PFI.[17-21] The paclitaxel-carboplatin combination, for example, has been shown to lead to a longer overall survival (OS) compared with platinum alone. However, combination therapy is more toxic. Selection of single-agent platinum vs combination platinum-containing regimens should also take into account patients’ performance status and previously encountered chemotherapy toxicities.
In two parallel randomized phase III trials, 802 women with platinum-sensitive recurrent ovarian cancer were treated with a single-agent platinum vs paclitaxel in combination with a platinum agent. The combination regimen was associated with an improved OS (hazard ratio [HR] = 0.82), a 2-year survival benefit of 7%, and 5 months’ improvement in median survival (29 vs 24 months). The combination regimen had a progression-free survival (PFS) with a HR of 0.76, and an absolute 10% difference in 1-year PFS (50% vs 40%). However, the combination was also associated with a higher incidence of grade 2 to 4 neurologic toxicity (20% vs 1%) and alopecia (86% vs 25%). Importantly, 30% of patients had been treated with platinum alone in the primary setting, for tumors that were taxane-naive at time of their entry into the study.
A second phase III trial of single-agent carboplatin compared with a platinum-containing doublet confirmed the observation that doublets are superior to single agents. In the Intergroup trial of the Arbeitsgemeinschaft Gynaekologische Onkologie-OVAR, the National Cancer Institute of Canada Clinical Trials Group, and the European Organisation for Research and Treatment of Cancer Gynecologic Cancer Group, carboplatin and gemcitabine were associated with a longer PFS vs carboplatin alone. The reported PFS for patients randomized to carboplatin was 5.8 months, compared with 8.6 months for patients treated with carboplatin and gemcitabine, (P = .0031; HR = 0.72; 95% CI, 0.57–0.90). The study was not powered to show an OS difference. The results of this trial resulted in the US Food and Drug Administration approval of combination gemcitabine plus carboplatin in platinum-sensitive second-line ovarian cancer in 2006.
In a phase III trial comparing two doublets, taxol and carboplatin vs carboplatin in combination with pegylated liposomal doxorubicin (PLD [Doxil]), PFS with the latter regimen (11.3 months) was not inferior to the taxane-containing doublet (9.4 months; P < .001; HR = 0.82; 95% CI, 0.72–0.94].
The angiogenesis inhibitor bevacizumab (Avastin) has been studied as a treatment option in both first-line ovarian cancer therapy and in patients with recurrent epithelial ovarian cancer.[20-24] The phase III OCEANS study randomized women with platinum-sensitive recurrent ovarian cancer to carboplatin plus gemcitabine with or without bevacizumab for 10 cycles maximum, followed by bevacizumab alone until disease progression or toxicity.[23,24] Compared with chemotherapy plus placebo, bevacizumab with chemotherapy was associated with an improved PFS (12 months with bevacizumab vs 8 months in the placebo group; HR = 0.48; 95% CI, 0.39–0.61), a higher response rate (79% vs 57%, P < .001) and a higher rate of treatment discontinuation for adverse events (23% vs 5%); the latter included higher rates of serious hypertension (17% vs < 1%), proteinuria > grade 3 (9% vs 1%), and non–central nervous system bleeding (6% vs 1%). Notably, there were no cases of gastrointestinal perforation reported during therapy. Overall survival was similar at 35 months of follow-up (33 vs 35 months).[23,24] The Gynecologic Oncology Group (GOG) is conducting a phase III randomized trial to evaluate the role of carboplatin and paclitaxel, with or without bevacizumab, in platinum-sensitive ovarian cancer. Table 2 summarizes these phase III combination trials in platinum-sensitive recurrent ovarian cancer.
Non–platinum-based combination regimens are another emerging option for patients with platinum-sensitive disease. In a phase III randomized trial of PLD alone vs PLD combined with the marine-derived alkaloid trabectedin (Yondelis), the combination regimen resulted in improved PFS.
Single-agent chemotherapy beyond second-line treatment
There are numerous single-agent therapeutic options or patients with platinum-sensitive ovarian cancer. Table 3 lists some of these chemotherapeutic options and their documented response rates.[26-49] The higher response rates are for patients with platinum-sensitive disease. These agents are appropriate for patients with platinum-sensitive recurrent ovarian cancer who have had progression of disease on platinum-based second-line therapy.
Bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, has been studied in several phase II studies alone and in combination with cytotoxic chemotherapy. It has been shown to be an active agent in patients with recurrent ovarian cancer.[20-24] The risk of gastrointestinal complications, specifically perforations, has been estimated to be 5% to 7%.[20-22] Some have suggested that bevacizumab should be used only in patients without clinical symptoms of bowel obstruction, CT scan evidence of bowel involvement, or evidence of rectosigmoid involvement on pelvic examination. The role of bevacizumab in the management of epithelial ovarian cancer is evolving, with two phase III studies of upfront treatment and the OCEANS study in platinum-sensitive disease showing an improved PFS when bevacizumab is used with chemotherapy and as maintenance therapy. However, these trials have failed to show an OS advantage. Thus, for patients with recurrent platinum-sensitive disease, it may be more appropriate to use combination chemotherapy alone as second-line therapy, rather than combination chemotherapy plus bevacizumab. Bevacizumab may be appropriate to use in combination with single-agent therapy for subsequent lines of treatment or as single-agent therapy.
Maintenance therapy in platinum-sensitive recurrent ovarian cancer
Several clinical trials have evaluated the role of agents aimed at prolonging the second remission. One of these is the OCEANS trial, evaluating the role of bevacizumab, as noted above, in combination with chemotherapy and as maintenance therapy.
In a trial of 296 women with platinum-sensitive recurrent ovarian cancer who achieved a response to their most recent line of therapy, patients were randomized to placebo or the poly ADP-ribose polymerase (PARP) inhibitor olaparib (at 400 mg orally twice a day). An improved PFS benefiting patients receiving olaparib was reported (8 vs 5 months; HR = 0.35; 95% CI, 0.25–0.49). At interim analysis, there was no OS difference (30 months in both; HR = 0.94; 95% CI, 0.63–1.39). Olaparib was associated with a higher rate of adverse events of all grades, including nausea (68% vs 35%), fatigue (49% vs 38%), vomiting (32% vs 14%), and anemia (17% vs 5%).
Other agents are the subject of ongoing clinical trials. The folate receptor is overexpressed in approximately 90% of ovarian cancers. Farletuzumab, a humanized monoclonal antibody to the folate receptor alpha, has been the subject of a phase II study. Patients with platinum-sensitive recurrent ovarian cancer were treated with either single-agent farletuzumab or, if symptomatic, a combination regimen of paclitaxel, carboplatin, and farletuzumab. The reported overall response was 70%, with a median PFS of 10.9 months. In a phase III trial, women with measurable, platinum-sensitive recurrent ovarian cancer were randomized to paclitaxel and carboplatin with or without farletuzumab. Farletuzumab in combination with carboplatin and a taxane did not meet the study’s primary endpoint of PFS. In the post hoc exploratory analysis, a trend toward improved PFS in some patient subsets was noted. Further analysis of the findings is ongoing.
Another agent, iniparib, may be an irreversible PARP inhibitor potentially with other cytotoxic actions. In a phase II trial, iniparib, given in combination with carboplatin and gemcitabine, resulted in a 65% response rate and a PFI of 9.5 months in 41 women with platinum-sensitive recurrent ovarian cancer.